Human Vaccines & Immunotherapeutics · 2017 · 13 citations · 9 references
Veterinary MedicineInfectious DiseasesPreventive MedicineImmunizationPublic Health SurveillanceVaccinologyAdverse Events Following ImmunizationEnhanced SurveillanceInfluenza-like Illness SurveillanceVaccinationVaccine SafetyVaccine Safety SurveillanceAdverse Event Reporting RatesAdverse Reactions ReportingAdverse Vaccine ReactionsImmunization ReportingImmunization Safety SurveillanceSeasonal Influenza VaccinesSuspected Adverse Reaction AssessmentVaccine Safety Reporting
Passive enhanced safety surveillance (ESS) was implemented in the United Kingdom and in the Republic of Ireland for Vaxigrip and Intanza 15 µg influenza vaccines during the 2016/17 influenza season. Lessons learned during 2015/16 ESS implementation were integrated and applied towards the current ESS. The primary objective was to estimate the reporting rates of suspected adverse reactions (ARs) occurring within 7 days of vaccination with Vaxigrip or Intanza 15 µg. For Vaxigrip (N = 962), 17 vaccinees (1.8%) reported 59 suspected ARs (6.1%) within 7 days of vaccination. For Intanza 15 µg (N = 1000), 21 vaccinees (2.1%) reported 101 (10.1%) suspected ARs within 7 days of vaccination. No obvious pattern in the type of suspected ARs or their frequency was observed for either vaccine. None of the frequencies of suspected ARs were above the 2015/16 ESS frequencies for Vaxigrip, whereas for Intanza 15 µg only one AR (oropharyngeal pain) crossed the historical threshold. There was no change in reactogenicity and data was consistent with the safety profiles of the two vaccines. The passive ESS experience gained from season to season will help to contribute to a sustainable safety surveillance system of seasonal influenza vaccines early in the season.
9
Vaccines against influenza WHO position paper – November 2012.
PubMed · 2012 · 793 citations
Claudia Vellozzi, Karen R. Broder, Penina Haber et al. · Vaccine · 2010 · 123 citations